S 2348 establishes grants to help sexual assault programs partner with health, behavioral health, disability, and community services to better support survivors. It directly affects State/tribal coalitions, nonprofit sexual assault programs (like rape crisis centers), and Indian tribes. The bill funds trauma-informed, culturally relevant services - including therapy, housing, and case management - while requiring privacy protections and program evaluations. It authorizes $30 million annually from 2026-2030 to improve comprehensive care for survivors, including adult survivors of childhood sexual assault.
The Rural Development Hospital Technical Assistance Program Act of 2025 establishes a new program within the Department of Agriculture to provide tailored technical assistance to eligible rural hospitals and clinics. It directly affects facilities like critical access hospitals, rural health clinics, and other designated rural health care providers in underserved areas, particularly those facing financial challenges or located in health professional shortage zones. The program helps these facilities identify development needs (such as facility upgrades, telehealth expansion, or health IT systems), improve financial management, and access USDA loan and grant programs. Authorized funding is $2 million annually for fiscal years 2025-2029, with mandatory annual reports to Congress on program outcomes and effectiveness.
HR 7391, the Community Health Center Drug Pricing Protection Act, requires that Federally Qualified Health Centers (FQHCs) pay the discounted 340B ceiling price for covered drugs **at the time of purchase**, not later through rebates or adjustments. This directly affects FQHCs, which rely on 340B discounts to provide affordable care to low-income patients. The bill amends the Public Health Service Act to prohibit manufacturers from entering agreements where FQHCs initially pay more than the ceiling price, with later reimbursement. It takes effect immediately upon enactment for all new drug purchases and applies to existing agreements starting then.
The Medicare Dental, Hearing, and Vision Expansion Act of 2025 would expand Medicare Part B coverage to include dental, hearing, and vision services starting in 2027. This would cover preventive dental services at 100% and other dental services at 80%, hearing aid examinations and hearing aids at 80%, and routine eye exams at 80% with frequency limits (such as two dental cleanings per year). The bill includes $900 million for dental, $370 million for hearing, and $500 million for vision implementation funding, affecting approximately 65 million Medicare beneficiaries who currently pay out-of-pocket for these services.
This bill requires every Department of Veterans Affairs (VA) medical center to provide dedicated lactation spaces for women veterans and the public. It mandates these spaces be private, accessible (including for wheelchair users), equipped with seating and a surface, clearly marked, and free from bathroom use. The law directly affects women veterans and other users who need to express breast milk at VA facilities. The VA must implement these changes within two years of the bill's enactment.
The 340B PATIENTS Act of 2025 clarifies that drug manufacturers must offer discounted prices under the 340B program to covered entities - such as community health centers, hospitals, and clinics - regardless of how or where drugs are dispensed, including through contracted pharmacies. It prohibits manufacturers from imposing restrictions on covered entities, such as limiting delivery locations, requiring extra data, or restricting how discounted drugs are used. The bill also establishes civil penalties for violations, including daily fines of up to $2 million, and allows covered entities to file claims for breaches of these rules. This ensures that covered entities can continue using contract pharmacies to access specialty drugs for patients with chronic or serious conditions.
The Expanding Access to Palliative Care Act (S 1935) creates a new 5-year Medicare model to provide community-based palliative care for beneficiaries with serious illnesses like cancer, heart disease, dementia, or kidney disease. It directly affects Medicare beneficiaries who need symptom management and care coordination, including those who previously used hospice care (who cannot be excluded). The bill requires 24/7 access via telehealth or in-person care, a team-based approach with certified palliative specialists, and aims to reduce unnecessary emergency visits and hospitalizations. Key provisions include eliminating hospice history barriers, requiring care coordination across settings (including homes and hospitals), and measuring outcomes like emergency department use and patient experience.
This bill requires most health insurance plans to cover HIV prevention services - including PrEP and PEP drugs, related lab tests, counseling, and monitoring - without cost-sharing (like copays or deductibles) or prior approval. It applies to private insurance, Medicare, Medicaid/CHIP, and federal employee health plans, directly affecting people who use HIV prevention medications. Key provisions mandate 100% coverage for FDA-approved HIV prevention drugs, eliminate cost-sharing for these services, and prohibit insurers from requiring preauthorization for them. The bill defines covered services to include all necessary components of HIV prevention care as outlined in current public health guidelines.
This bill modifies requirements for pediatric drug studies, particularly for drugs treating rare diseases (orphan drugs). It requires the FDA to issue a noncompliance letter and allow 45 days for response before imposing penalties, and creates an automatic FDA waiver list for diseases where pediatric studies are impractical. Drug sponsors developing orphan drugs for rare conditions will benefit from clearer pathways, as the bill specifies when pediatric studies aren't required unless they offer meaningful therapeutic benefit. The FDA must also report on penalties for noncompliance and update its waiver lists, aiming to streamline development while improving pediatric data for rare diseases.
S 329, the Keeping Drugs Out of Schools Act of 2025, authorizes federal grants to fund partnerships between local anti-drug coalitions and schools to implement evidence-based drug prevention programs. It directly affects elementary, middle, and high schools in communities with existing Drug-Free Communities coalitions, providing up to $75,000 per school annually for these partnerships. The bill requires grantees to submit detailed implementation plans and use funds to supplement, not replace, existing prevention funding. It allocates $7 million yearly (2026-2031) for these programs, with no more than 8% of funds allowed for administrative costs.
